Synapse - Alison Moskowitz

Results (360)

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)

Meeting Abstract

Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2017)

Fulltext@MSK | Save

Relapsed and refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A.
Clinical Lymphoma, Myeloma and Leukemia (2017)

Fulltext@MSK | Save

Clinical outcome and prognosis of young patients with mycosis fungoides

Journal Article

Virmani, P.; Levin, L.; Myskowski, P. L.; Flores, E.; Marchetti, M. A.; Skripnik Lucas, A.; Pulitzer, M.; Horwitz, S.; Trippett, T.; Moskowitz, A.; more...
Pediatric Dermatology (2017)

Fulltext@MSK | Save

Utility of imaging in cutaneous marginal zone lymphoma

Meeting Abstract

Geller, S.; Dai, J.; Myskowski, P.; Kim, Y. H.; Moskowitz, A.; Pulitzer, M.; Hoppe, R.; Horwitz, S. M.; Kheterpal, M.
Journal of Investigative Dermatology (2017)

Fulltext@MSK | Save

The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma

Journal Article

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium

Meeting Abstract

Lunning, M.; Horwitz, S.; Mehta-Shah, N.; Moskowitz, A.; Advani, R.; Beaven, A.; Haverkos, B.; Lechowicz, M.; Oki, Y.; Zain, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Interim results from a Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; Lacasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save